European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC expressing PD-L1: Rahway, New Jersey Thursday, October 30, 2025, ...
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects ...
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
News Medical on MSN
Boosting First Responder Cells May Aid Cancer Therapy
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard ...
Thank you, operator. Good morning and good afternoon, everybody, and thank you for joining BioNTech's Third Quarter 2025 Earnings Call. As a reminder, the slides we'll use during the call and the ...
OncoHost, a global leader in precision oncology and proteomics-based biomarker development, today announced the presentation of two new research posters at the 2025 International Society for Liquid ...
4d
Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...
Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, British Columbia, Saskatchewan, Nova Scotia, Newfoundland and ...
In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). In combination with everolimus, for the treatment of adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback